For instance, IFN-γ enhances ICAM-1–mediated CAR T-cell cytotoxicity against various types of solid tumor but not the leukemia, lymphoma, or myeloma CDX models (114), although this different IFN-γ sensitivities are unclear in clinical level. Here, ICAM1 is linked to plasma cell myeloma.